If you've dealt with recurrent urinary tract infections after menopause, you've probably heard that vaginal estrogen can help. What you may not have heard is just how strong that evidence is, or how underused this treatment still is in everyday practice.
A newly published randomized trial adds an important new piece to the evidence around how local vaginal estrogen can be used for preventing recurrent UTIs in postmenopausal women. And it surfaces a question central to how we think about care at Good Clean Clinical Care: the active hormone is only part of a vaginal formulation. The base that delivers it can influence local tolerability and epithelial compatibility and may matter for maintaining a vaginal environment supportive of healthy microbiota.
What the New Study Found
The TAPER trial (Techniques of Applying Vaginal Estrogen for Prevention of Recurrent Urinary Tract Infections), published in Obstetrics & Gynecology, compared two ways of applying the same estradiol cream in postmenopausal women with a history of laboratory-confirmed recurrent UTIs: the standard intravaginal applicator method using 1 g twice weekly, and a simpler periurethral (around the urethra) application using 0.5 g twice weekly.
The conclusion: "For postmenopausal individuals who are experiencing recurrent UTI, periurethral application of estradiol cream is noninferior to intravaginal application for UTI prevention. Both application methods resulted in approximately half of the participants being UTI-free at 6 months." Specifically, 52.6% of the intravaginal group and 50.9% of the periurethral group were UTI-free at six months. At three months, vaginal itching was reported by 24.0% of the intravaginal group compared with 2.4% of the periurethral group.
In other words, women now have more than one evidence-supported way to use vaginal estrogen effectively, including an option that may be easier for those who find a vaginal applicator uncomfortable or difficult to use. This matters because vaginal estrogen already is recommended by major clinical guidelines for peri- and postmenopausal women with recurrent UTIs when there is no contraindication, yet it remains significantly underprescribed and underused. Every study that expands the evidence base, and the range of ways patients can actually stick with treatment, is worth celebrating.
There's Rarely a One-Size-Fits-All Answer
Roughly half of participants in both groups were UTI-free at six months. Because both groups received estradiol, TAPER was not designed to measure the efficacy of vaginal estrogen compared with placebo or no treatment. That's not any evidence against vaginal estrogen, but rather a reminder of something we see constantly in vaginal and urogenital health: individual response varies enormously, and no single dose or application method works identically for every body.
More evidence around formulation and application gives patients and providers more room to actually find what works for the individual, which is a direction this field has needed to move in for a long time.
Why the Base Matters Too
Here's where we think the conversation needs to go further: Vaginal estrogen is available in several dosage forms, including creams, tablets or inserts, and rings, and it can also be compounded. When estrogen is delivered in a cream or compounded vehicle, the formulation can matter for comfort and mucosal compatibility. Depending on their osmolality, pH, and ingredient profile, some of these bases can affect epithelial integrity and irritation potential. Hyperosmolar vaginal products have been shown in laboratory models to compromise epithelial barrier properties, and separate in vitro studies have shown that some vaginal formulations can inhibit the growth of health-associated Lactobacillus species.
Anecdotally, we’ve heard women raise concerns about the ingredients that many of these bases use. For example, some vaginal products can contain relatively high concentrations of humectants such as glycerin or propylene glycol. While glycerin is commonly used as a humectant and formulation ingredient, at a higher concentration it can contribute to a more hyperosmolar environment. We've heard from women who report experiencing recurrent or new episodes of thrush after using certain vaginal estrogen cream formulations, leading them to question whether the formulation itself may be contributing to their symptoms or causing new ones. Importantly, available evidence does not establish whether these symptoms are attributable to estrogen, the vehicle, or both.
That's a problem, because the goal of local estrogen therapy for recurrent UTIs isn't just to deliver estradiol, but to restore estrogen-responsive urogenital tissue, improve epithelial maturation, lower vaginal pH, and often increase Lactobacillus abundance, changes that are thought to contribute to reduced recurrent UTI risk after menopause. For that reason, it makes sense to consider formulation compatibility alongside hormone delivery.
This is exactly why every Good Clean Clinical Care prescription is compounded in BiomeNourish™, a prescription base formulated specifically for the vaginal and vulvar microbiome. Built with our patented Bio-Match® Technology, BiomeNourish™ is designed to be iso-osmotic and pH-matched to the vagina's natural biology, and includes a proprietary lactic acid blend selected to align with the vagina’s naturally acidic environment.
In practice, that means we think about both the active prescription and the vehicle that delivers it, with the goal of supporting treatment while minimizing unnecessary formulation-related irritation or disruption.
More Evidence, More Options, More Individualized Care
Findings like the TAPER trial expand the evidence base, offer more application options, and support more personalized care for a condition that too often gets treated with repeat rounds of antibiotics without addressing an important menopause-associated contributor to recurrent UTI risk. We hope to see local estrogen therapy, and thoughtful conversations about the base it's delivered in, become a more routine part of individualized recurrent UTI care for postmenopausal women.
If you're navigating recurrent UTIs and want to talk to a provider about whether vaginal estrogen compounded in a microbiome-friendly base is right for you, Good Clean Clinical Care is here to help.
Sources:
Zuo SW, Mowers EE, Hem S, Bradley M, Zyczynski HM, Hillier SL, Ackenbom MF. Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial. Obstet Gynecol. 2026 Jul 27. doi: 10.1097/AOG.0000000000006376. PMID: 42492951.
American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. Recurrent Uncomplicated Urinary Tract Infections in Women: Guideline, amended 2025. Recommendation 20 addresses vaginal estrogen for peri- and postmenopausal women with recurrent UTI.
Ayehunie S, Wang YY, Landry T, Bogojevic S, Cone RA. Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model. Toxicol Rep. 2018;5:134-140. PMID: 29854584.
Wilkinson EM, Łaniewski P, Herbst-Kralovetz MM, Brotman RM. Clinical and personal lubricants impact growth of vaginal Lactobacillus species and colonization of vaginal epithelial cells: an in vitro study. Sex Transm Dis. 2022;49(1):63-70.